The Market Herald - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Neuroscientific Biopharmaceuticals (NSB) has released an underwhelming study for its Alzheimer’s treatment
  • The company had a breakthrough in July but has since struggled to bring in more strong results
  • Apparently, there is a lack of animals that replicate the disease as it occurs in humans
  • Neuroscientific’s share price crashed today, dropping 28.81 per cent to 21 cents per share.

Neuroscientific Biopharmaceuticals (NSB) shares have suffered a mighty blow after some underwhelming results from its latest EmtinB study.

The company saw a major breakthrough in its EmtinB treatment’s potential to treat Alzheimer’s Disease in early July, resulting in shares spiking from 14 cents each to 42 cents each in one day.

Today, however, the company announced it is struggling to pull further strong results from another mouse study.

July’s study showed the drug’s ability to repair damaged neurons, paving the way for breakthrough Alzheimer’s treatments. But the company said today there is a lack of animals that replicate the disease as it occurs in humans — which means translating the treatment from mouse or pig studies into humans can be tough.

The latest EmtinB study showed the treatment had no effect on reducing neuroinflammation — or the swelling of brain tissue — in the test subjects, which were in this case mice.

The company found the treatment “could be” effective at reducing gamma-Aminobutyric acid, known as GABA, which is a type of acid that acts as a neurotransmitter in your brain. GABA is one of the identifiers of Alzheimer’s disease.

While the study perhaps failed to yield the results Neuroscientific might have hoped for, CEO and Managing Director Matthew Liddelow said the study has still given the company some valuable information.

“While the cognitive data set appears inconclusive, we are pleased with the results on the whole as it builds our deeper understanding of this unique molecule and its correct application in the neuroscience field,” Matthew said.

Still, the market seemed disappointed with the company’s update.

Neuroscientific shares slumped 28.81 per cent today, dropping from 30 cents to 21 cents by market close. Neuroscientific’s market cap is valued at $16.46 million.

NSB by the numbers
More From The Market Herald

The Calmer Co locks in $700k in funding via convertible note issue

The Calmer Co (ASX:CCO) has confirmed its receipt of $700,000 in funding from existing shareholders.

FDA greenlights Botanix Pharmaceuticals’ Sofdra resubmission plan

FDA approves Botanix's strategy for Sofdra NDA resubmission with no additional materials requested, keeping submission to…

Botanix Pharmaceuticals successfully closes $13.5m Placement to boost US commercial activities

Botanix Pharmaceuticals (ASX: BOT) has closed its $13.5 million placement to both new and existing institutional…

Pharmaust completes Phase One Monepantel study and files for Orphan Drug Designation

Pharmaust (ASX:PAA) has announced that all patients have completed its phase one MEND study using monepantel…